

# QUANTEX FUNDS - NEBENWERTE SCHWEIZ R

Investment fund under Swiss law - Investments in Swiss small & mid caps

November 2024

Market data (Quantex, Bloomberg) of November 29, 2024

# **Fund Features**

Currency Denomination CHF

Inception Date August 31, 2008 Domicile Switzerland

Fund Management 1741 Fund Solutions AG, St. Gallen
Custodian Bank Regiobank Solothurn AG, Solothurn
Investment Manager Quantex AG, Muri bei Bern
Auditor Grant Thornton AG, Zürich

Auditor Grant Thornton AG, Zürich
Distribution none (accumulation)
Comparison Index SPI Swiss Small Companies Index /

OTC-X Liquidity Index Subscription/Redemption daily, until 2:30 pm by the custodian bank

Distribution License CH
Tax Compliance AT,DE

Publication Medium www.swissfunddata.ch

Swiss Security Number 4343142
German WKN A0YBJ8
ISIN Number CH0043431425
Bloomberg Ticker QUANTEX SW

Total Expense Ratio 2.11% per 06/30/2024
Administration Fee 2.2% p.a. max
thereof Management Fee 1.75% p.a.

Max. Issuing Commission 2.0%
Swing Pricing 0.15%

#### **Current Data**

Net Asset Value	CHF	210.75
52 Week High	CHF	222.32
52 Week Low	CHF	202.40

Total Assets in mn CHF 7.30 (all classes of the fund)

Number of Shares 19'117

# **Investment Objective and Investment Policy**

The Quantex Nebenwerte Fonds Schweiz aims for a return above average withinvestments in undervalued shares of small and midsized companies domiciled in Switzerland. A lower volatility of the fund shall be achieved through a stake of up to 30% in Swiss OTC stocks not traded at an organized and regulated market.

# Characteristics

The investment fund is suitable for long term investors who seek capital gains, have an investment horizon of at least five years and are able to bear price fluctuations. The investment fund is suitable as an addition to a broadly diversified equity portfolio.

# Investment Manager's Comment

In November, the main focus of the financial markets was on the surprisingly clear election of Donald Trump as the new US president. His announcements of import tariffs were the main cause of uncertainty. While the American stock markets gained strongly, the picture in Europe was mixed. The Swiss indices even suffered losses.

Compagnie Financière Tradition reported increasing sales in the third quarter. The half-year figures for Burckhardt Compression showed surprising order intakes, which exceeded the expectations. Ypsomed was also convincing. The growth in insulin pump sales suggests a good negotiating basis for the sale of the division.

During the reporting month, we completely sold our positions in **Banque Cantonale du Jura**, **Klingelnberg** and **Romande Energie**, thereby reducing the proportion of illiquid listed Swiss equities.

#### Net Asset Value in CHF




# Net Performance in CHF (fund after fees, index without fees)


	Nov 24	YTD	1 Year	5 Years	10 Years	Incept.*
Nebenwerte Schweiz R	-1.3%	0.3%	2.8%	10.4%	39.5%	110.8%
SPI Swiss Small Companies Index	-1.6%	-4.1%	-1.5%	6.5%	49.2%	118.6%
OTC-X Liquidity Index	-0.8%	-4.4%	-3.8%	-13.4%	10.7%	7.0%

<sup>\*</sup>inception on 08/31/2008.

# **Asset Allocation**



# Sectors



# Top Holdings

Mid	Can	Companies	

YPSOMED HOLD-REG DKSH HOLDING LTD SKAN GROUP AG	2.8% 2.7% 2.5%	BURKHALTER HLDG BELL FOOD GROUP AG EMMI AG	2.5% 2.4% 2.4%
Small Cap Companies (< 500	mn USD)		
CPH GROUP	2.6%	V-ZUG HOLDING	2.2%
MIKRON HLDG-RG N	2.4%	LAGERHAEUSER DER	1.2%
		CENTRALSCHWEIZ (OTC-X)	
MEIER TOBLER GROUP	2.3%	CICOR TECHNO-REG	1.0%

This publication is a marketing information, is exclusively for informational purposes and does not constitute an offer or invitation to invest in the mentioned product. The completeness or correctness of this publication is not guaranteed. Investments can involve significant risks and the value of an investment may go down as well as up. Past performance is not indicative of future results. Units of investment funds mentioned in this publication may not offered, sold or delivered in certain jurisdictions, or to persons affiliated with certain jurisdictions or to persons affiliated with certain jurisdictions or to persons affiliated with certain jurisdictions or to person affiliated with certain jurisdictions or to person affiliated with certain jurisdictions or to person affiliated with certain jurisdictions or to any US person (within the meaning of Regulation S under the US Securities Act of 1933, as amended). The performance shown does not take account of any commissions and costs charged when subscribing and redeeming units. Investments in this product occur exclusively based on the following documents: Prospectus with integrated fund contract, key information document or PRIIP-KID as well as annual and semi-annual reports. They are available free of charge at www.swissfunddata.ch or at 1741 Fund Solutions AG, Burggraben 16, CH-9000 St. Gallen.